NK2022

Poster Sessions

POSTER SESSION I: Sunday, May 15

Jump to Poster Session II

23  A Phase I Study of Universal-Donor TGFß-Imprinted NK Cell Therapy in Combination with Carboplatin for Canine Osteosarcoma
Aarohi Thakkar, M.S., Nationwide Children's Hospital

24  Inhibition of NK and myeloid cell inhibitory receptor interactions by anti-MHC-I augments innate and adaptive immunity in both mouse and man.
Abir K. Panda, NIAID, NIH

25  Universal prospects of cryopreserved “off-the-shelf” umbilical cord blood CD34+ progenitor cell-derived NK cell therapeutics: Clinical and preclinical evaluation of GTA002 and genetically modified candidates
Adil D. Duru, Glycostem Therapeutics B.V.

26  A Tri-specific Killer Engager against B7-H3 (GTB-5550) enhances Natural Killer cell mediated killing of multiple myeloma
Aimee M. Merino, MD PhD, University of Minnesota

27  NKG2A Knock-out Natural Killer Cell overcome Human Leukocyte Antigen E mediated inhibition and improve Chimeric Antigen Receptor NK anti-tumor activity against solid tumor
Alice Mac Donald, University of Montreal

28   Overcoming barriers to the NK cell response against multiple myeloma: manipulating the NKG2A/HLA-E checkpoint and CAR engineering of memory-like NK cells
Alice Y. Zhou, Washington University School of Medicine

29  Multimodal activation of ex vivo expanded GTA002 NK cells efficiently targets melanoma
Amanda A. Van Vliet, Glycostem Therapeutics

30  Dysregulated DNAM-1 and KIR2DL1 expression in CD56dim NK cells correlates with poor outcome in Acute myeloid leukemia
Amanda Costa, University of Sao Paulo

31  Development of a Natural Killer cell manufacturing platform
Angela Mekes, Miltenyi Biotec B.V. & Co. KG

32  Engineering TGF-ß resistant NK cells
Anna Rea, Pompeu Fabra University

33  Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
Anne Scherer, MSc, Georg Speyer Haus

34  Harnessing CD70-directed chimeric antigen receptor natural killer cells with interleukin 15 is necessary to eradicate solid tumor cells and cancer-associated fibroblasts
Astrid Van Den Eynde, Center for Oncological Research

35  Investigating the crosstalk between NK Cells and Cancer associated Fibroblasts in the Tumor Microenvironment and its role in Driving Malignancy
Aviad Ben-Shmuel, Weizmann Institute

36  Improved anti-tumor Activity via Combined use of iPSC-Derived Natural Killer Cells with Macrophages and anti-CD47 Blockade
Benjamin Goldenson, MD, PhD, UC San Diego

37  Miniaturized and multiplexed evaluation of NK cell cytotoxicity against patient-derived sarcoma spheroids in a novel multichambered microwell chip
Bjorn Onfelt, KTH - Royal Institute of Technology

39  IMPLICATIONS OF THE RUXOLITINIB (JAK1/JAK2 INHIBITOR) ON GRAFT-VERSUS-LEUKAEMIA EFFECT MEDIATED BY THE NK CELL.
Carmen Mestre Duran, Hospital Universitario La Paz

40  Impacts of Heparin versus Acid Citrate Dextrose Solution A (ACD-A) on Natural Killer (NK) Cells from Peripheral Blood Collection
Catherine A. Cash, Nationwide Children's Hospital

41  A clinical-grade manufacturing platform using CliniMACS Prodigy for CAR-NK cell-based immunotherapy
Congcong Zhang, Miltenyi Biotec B.V. & Co. KG

42  Comparative analysis of tissue-resident NK cells, T cells, and ILCs in distinct areas of human lung tumor tissue
Demi Brownlie, Karolinska Institutet

43  Efficient scale-up and pre-clinical evaluation of single-self-KIR+NKG2C+ adaptive NK cells for therapy against high-risk AML/MDS
Ebba Sohlberg, Karolinska Institutet

45  ILC1-like cell expansion is driven by CXCR3-dependent macrophage accumulation in colorectal cancer liver metastasis
Eleonora Russo, Sapienza University of Rome

46  Characterization of a subset of tissue resident NK cells in ovarian cancer ascites with anti-tumor properties
Elin Bernson, University of Cambridge

47  Evaluation of CD38-KO/CD38-CAR Human Primary Natural Killer Cells against CD38-expressing Lymphoma, Leukemia, and Myeloma
Ella C. Troy, BS, Nationwide Childrens Hospital

48  Epigenetic and post-transcriptional regulation of B7H6 surface expression by cancer cells
Ellen Sofie Pete, University of Oslo, Norway

49  T-cell receptor engineering of primary NK-cells to therapeutically target tumours and tumour immune evasion
Els P. Van Hees, Leiden University Medical Centre

50  Expansion of NK cells for allogenic cell therapy
Erica L. Heipertz, PhD, Thermo Fisher Scientific

51  Primary CD33-targeting chimeric antigen receptor-modified NK cells efficiently target acute myeloid leukemia
Evelyn Ullrich, Goethe University Frankfurt

52  New molecular targets to overcome immune therapy resistance
Faith O. David, St. Anna Children's Cancer Research Institute GmbH

53  Improved leukemia clearance following adoptive transfer of NK cells engineered to overexpress the gain-of-function bone marrow homing receptor CXCR4-R334X
Filip Segerberg, Karolinska Institutet

54  Nicotinamide promotes natural killer cell homing, metabolism, and antitumor function for enhanced immunotherapy
Frank Cichocki, University of Minnesota

55  Contribution of CMV viremia in the expansion of cytokine induced memory-like NK cells in patients with post-transplant relapse
Grace C. Birch, PhD, BSc, Dana Farber Cancer Institute

56  Development of an iPSC-derived NK cell screening platform for discovery of NK cell optimized Chimeric Antigen Receptors (CARs) for next-generation CAR-NK cell immunotherapies
Huang Zhu, Shoreline Bioscience

57  Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies
Ilona Hagelstein, German Cancer Consortium

58  Development of a 3-dimensional head and neck cancer cell culture model for the assessment of NK cell-based therapies
Ioana Sonya Ciulean, Fraunhofer-Institut Fur Zelltherapie Und Immunologie

59  Hypoxia Inducible Factor-1a deficiency unleashes human NK cell function in hypoxic solid tumors
Irene Garces-Lazaro, Universität Heidelberg

60  Exploring Mechanisms of Activating-Receptor Induced Exhaustion in Human NK Cells
Jacob Myers, University of Minnesota, Twin Cities

62  Disruption of TGF-b signaling pathway in human iPSC-derived NK cells promotes improved anti-tumor activity against hepatocellular carcinoma
Jaya Lakshmi Thangaraj, MTech, PhD, University of California San Diego

63  Optimization of cytokine support for adoptively transferred human NK cells in immunodeficient NSG mice
Jennifer Tran, Washington University School of Medicine in St. Louis

64  Novel bispecific innate cell engager AFM28 in combination with allogenic natural killer cells for the treatment of CD123-positive acute myeloid leukemia and myelodysplastic syndrome
Jens Pahl, PhD, Affimed GmbH

65  Combined use of cytokines and PM21-particle activation expands NK cells with memory-like features
Jeremiah Oyer, University of Central Florida

66  Targeted delivery of a PD-L1-blocking scFv by anti-B7-H3.CAR-NK cells shows potential as a new approach to immunotherapy for osteosarcoma
Jiao Wang, Purdue University

67  Dual targeting of CAR-NK cells to PD-L1 and HER2 facilitates specific elimination of cancer cells of solid tumor origin and overcomes immune escape by antigen loss
Paola Ortiz Montero, Dresden University of Technology

68  PARP inhibitors render otherwise resistant ovarian and breast carcinoma cells sensitive towards NK-cell mediated lysis
Jiri Eitler, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology

69   FLYSYN: Results of the first-in-human trial evaluating an Fc optimized FLT3 antibody in acute myeloid leukemia patients with minimal residual disease
Jonas S. Heitmann, University Hospital Tuebingen

70  CAR-NK cells expressing soluble interleukin-15 exhibit sustained antitumor activity
Jonathan Druge, Miltenyi Biotec B.V. & Co. KG

71  Bispecific antibodies binding to PD-L1 and NKG2D mediate selective targeting of NKG2D-CAR natural killer cells to PD-L1-positive tumor cells
Jordi Pfeifer Serrahima, PhD, Georg-Speyer-Haus

72  PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in multiple myeloma
Katharina H. Susek, Karolinska Institute

73  Arming of iPSC-derived NK cells Expressing a Novel CD64 Fusion Receptor with Therapeutic Antibodies as an Off-the-Shelf, Multi-antigen Tumor-targeting Strategy
Kathleen J. Dixon, University of Minnesota

74  Deletion of ADAM 17 in primary NK cells
Kinnari D. Sorathia, Nationwide Children's Hospital

75   Engineered iPSC-derived NK cells expressing a novel CD64 fusion receptor armed with multiple therapeutic antibodies to circumvent tumor heterogeneity in ovarian cancer
Kristin M. Snyder, University of Minnesota

76  Characterization of CRISPR/AAV Generated Anti-CD33 CAR NK cells for Acute Myeloid Leukemia
Kyle A. Beckwith, Ohio State University

77  Engineered induced pluripotent stem cell-derived natural killer cells reactively co-target TIGIT and CD73 in the glioblastoma tumor microenvironment
Xue Yao, Purdue University

78  Modulating natural killer cell metabolism by inhibiting Glucose Transporters reduces IFNg production but enhances serial killing
Lea Katharina Picard, Leibniz Research Centre for Working Environment and Human Factors

79  Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD Domain of HIF-1a
Lei Tian, City of Hope

80  PM21-particle expanded and cryopreserved Natural Killer cells retain their effector function in vitro and in vivo.
Liza Robles, University of Central Florida

82  Deletion of glycogen synthase kinase 3 beta in primary NK cells alters oxidative phosphorylation.
Marcelo De Souza Fernandes Pereira, Nationwide Childrens Hospital

83  A Direct Comparison of CAR NK Cells and CAR T Cells for CD19+ Malignancies.
Margaret Lamb, MD, NCH

84  Human Cytokine-Induced Memory-Like NK cells Demonstrate Increased Reactivity To Non-Small-Cell Lung Cancer Tumor Spheroids and Superior Ability to Eliminate CD133+ Cancer Stem Cells
Maria Guevara Lopez, University of Genoa

85  Low dose cytokine-activated characterization and proliferation of anti-tumoral NK cells
Maria Jose Felgueres, National Biotechnology Centre (CNB - CSIC)

86  Exploring the feasibility of CD38-targeting CAR-NK therapy for Multiple Myeloma by harnessing features of cytokine-expanded NK cells
Maria Karvouni, Karolinska Institute

87  IL-15 immunocytokines directed to CD135 and CD133 with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia
Martina S. Lutz, University Hospital Tuebingen

88  Development of WU-NK-101, a feeder cell-free expanded allogeneic memory NK cell product with potent anti-tumor activity
Mary Elizabeth Mathyer, PhD, Wugen

89  Irradiation enhances tumor surveillance by NK cells and their synergistic functions against both parental and stem-like liver cancer
Meesun Yoon, Chonnam National University Hwasun Hospital

90  NFAT1 and NFAT2 are major regulators in NK cell immunosurveillance
Melanie Maerklin, University Hospital Tuebingen

91  B7H3-Targeting Tri-specific Killer Engager (TriKE®) Induces Natural Killer Cell Activation and Antibody Dependent Cellular Cytotoxicity against Head and Neck Squamous Cell Carcinomas
Melissa J. Khaw, University of Minnesota Twin-Cities

92  How do leukemic cells escape natural killer cell-mediated surveillance? Uncovering novel immune evasion mechanism(s)
Michelle Claudine Buri, St. Anna Children´s Cancer Research Institute

93  Chimeric antigen receptor-NK cells against severe acute respiratory syndrome coronavirus 2
Mila Bjelica, University of Montreal

94  Comparative proteomics profiling of NK-cell derived extracellular vesicles from primary NK cells and cell lines reveal optimal composition for anti-tumor activity of extracellular vesicles
Miriam Aarsund Larsen, University of Oslo

95  Memory-like differentiation in combination with cetuximab and ephA2 chimeric antigen receptor (CAR) expressing memory-like NK cells exhibit potent response to head and neck cancer
Miriam T. Jacobs, Washington University

96  Differential phenotype and gene expression profiles of adaptive NK cell subsets in blood and tissue of cytomegalovirus positive glioblastoma patients
Mohummad Aminur Rahman, PhD, University of Bergen

97  Natural Killer cell engagers targeting CD19 boost NK cell activity against pediatric B-cell precursor acute lymphoblastic leukemia
Natalia Colomar Carando, IRCCS Ospedale Policlinico San Martino

98  Pre-Clinical Studies of Camelid Nanobody-based NK Cell Engager Molecules Targeting B7-H3
Nicholas Zorko, MD, PhD, University of Minnesota

99  Patient-derived three-dimensional-organoid models to study combination therapies of natural killer cells and antibody-dependent cellular cytotoxicity-inducing antibodies in pancreatic cancer
Nicky A. Beelen, Maastricht University

100  Enabling treatment options against colorectal cancer by enhancing functionality of stem cell derived NK cells
Nina Lamers, PhD, Glycostem Therapeutics

101  Uncovering a new NK-mediated pathway to tumor cell death by Natural Killer Lytic Associated Molecule (NKLAM) ubiquitin ligase activity
Paul A. Willard, St Louis University School of Medicine

102  Multiparametric analysis of NK cell reconstitution post-transplant to evaluate impact of graft sources in the setting of AML
Peter Hinderlie, University of Minnesota

103  The hypoxic tumor environment poses proliferative, metabolic and cytotoxic challenges to natural killer cell immunotherapy
Philippa Kennedy, University of Minnesota

104  Characterization of a novel subset of Natural Killer cells in autoimmune uveitis patients by single cell RNAseq
Pulak R. Nath, National Eye Institute, National Institutes of Health

105  Acute fasting induces anti-tumor immunity via natural killer cell redistribution
Rebecca B. Delconte, PhD, Memorial Sloan Kettering Cancer Center

106  Autologous expanded NK cells with dinutuximab for patients with relapsed/refractory neuroblastoma: manufacturing success and correlative studies on NANT2013-01
Robin J. Nakkula, Res. Inst. of Nationwide Childrens Hospital

107  Fatty acid oxidation fuels natural killer cell cytotoxicity and anti-tumor function
Sam Sheppard, Memorial Sloan Kettering Cancer Center

108  Safety analysis of canine natural killer cells expanded ex vivo in a mouse model of graft-versus-host disease
Sang-Ki Kim, Kongju National University

109  NK CELL ENGINEERING TO SPECIFICALLY TARGET SOLID TUMORS LIKE RHABDOMYOSARCOMA
Soraya Benhaddou, Sainte Justine Research Center

110  The Fc-optimized antibody 7C6-GAALIE promotes natural killer cell effector functions against acute myeloid leukemia
Stefanie Maurer, Icahn School of Medicine at Mount Sinai

111  Anti-tumor activity of NK cells in in vitro models of thymic tumors
Susanne Christine Kleiner, University of Heidelberg

112  Analysis of the longitudinal effects of AFM24, a CD16A/epidermal growth factor receptor-targeting bispecific innate cell engager, in patients with EGFR-expressing solid tumors
Susanne Wingert, Affimed GmbH

113  Knockout of the inhibitory receptor TIGIT enhances anti-tumor response of ex vivo expanded Natural Killer cells
Tayler J. Croom-Perez, PhD, University of Central Florida

114  Induction of PD-L1 on PM21-particle expanded Natural Killer cells and its effect on NK cell function
Tayler J. Croom-Perez, PhD, University of Central Florida

115  Non-viral engineering with the Sleeping Beauty transposon system yields CD19-CAR NK cells with a safe vector integration profile and high antileukemic efficiency
Tobias Bexte, Experimental Immunology, Childrens’ Hospital, University Hospital Frankfurt/M

116  Combinatorial effect of NKG2A and KIR receptors drives Interferon gamma-mediated melanoma resistance to NK cells.
Tomas Hofman, Mannheim Institute for Innate Immunoscience

117  Context- and Subset-dependent Natural Killer cell activation by interleukin-33 in tumors
Valentin Picant, Cancer Research Center of Lyon, CRCL

118  TIGIT dominates NK cell recognition of PVR levels on tumor cells leading to donor-dependent responses to checkpoint blockade
Valentina Carannante, Karolinska Institutet

119  Inflammatory cytokines perturb NK cell function and gene signature in acute and chronic myeloid leukemias
Valeriya Kuznetsova, University of Alabama at Birmingham

120  High-resolution natural killer cell phenotyping by mass cytometry in EBV+ and EBV- individuals
Wenming Zhang, Stanford University

121  KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
Ye Li, UT Health

122  A transformable three-dimensional simulated solid tumor culture model reveals widespread killing potential of natural killer cells with controlled lytic granule positioning
Yu Li, Columbia University

123  Natural killer cells release subsets of extracellular vesicles with distinct profiles and tumor-targeting abilities
Yunjie Wu, University of Oslo

124  An iPSC Derived NK cell controls glioblastoma multiformae in vivo as a direct injection cellular immunotherapeutic
Zachary B. Davis, PhD, University of Minnesota

POSTER SESSION II: Monday, May 16

147  Clinical process development of TGF-ß-imprinted IL-21-expanded NK cells
Aarohi Thakkar, M.S., Nationwide Children's Hospital

148  Evaluating the Impact of a Novel Beta Actin Variant as Cause of a Functional Natural Killer Cell Deficiency
Abigail E. Reed, Columbia University Medical Center

149  Partial restoring NK cell function by enhancing of non-canonical IL-2 signaling pathway in human STAT5b-deficient NK cells
Alexander Vargas-Hernandez, PhD, Texas Children's Hospital / Baylor College of Medicine

150  The role of adaptive Natural Killer cells during acute HIV-1 infection with different subtypes
Aljawharah Alrubayyi, University of Oxford

151  HARNESSING CX3CR1 ANTAGONISM TO PROMOTE NK CELL MIGRATION TOWARDS TUMOUR IN OBESITY ASSOCIATED CANCER.
Eimear Mylod, Trinity College Dublin

152  Tissue-specific NK cell responses during aGvHD
Amanda Sudworth, University of Oslo

153  Forecasting of Kidney Transplanted Rejection Using Multivariate analysis and Machine-Learning Algorithms: A 10-year Follows up, Single Center Study of Allograft Outcomes in Kidney Transplanted Recipients
Ameera Gaafar, PhD, King Faisal Specialist Hospital and Research Center

154  Fine-tuning NK cell responsiveness by the Aryl-hydrocarbon receptor
Ana Stojanovic, Heidelberg University

155  Profiling of natural killer cells in the critically ill to distinguish between sepsis and non-infectious systemic inflammation
Anna Coulibaly, Dept. of Anesthesiology & Surgical Intensive Care Medicine

156  Control of NK cell function in tissues: human intrahepatic CD56bright NK cells upregulate the co-inhibitory receptor TIGIT and downregulate the co-stimulatory receptor DNAM-1
Annerose E. Ziegler, MD, Leibniz Institute for Experimental Virology (HPI)

157  NKp44/HLA-DP-dependent control of HBV infection
Annika Niehrs, Leibniz Institute for Experimental Virology (HPI)

158  CD137 costimulation counteracts TGF-ß inhibition of NK cell anti-tumor function
Aura Muntasell, Hospital Del Mar Medical Research Institute

159  Induction of NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 after natural infection is more potent than after vaccination
Benjamin Kraemer, University of Bonn

160  HLA-DPA1*02:01|B1*01:01 is a risk haplotype for primary sclerosing cholangitis that enables NKp44 binding and activation of NKp44+ NK cells
Britta Franziska Zecher, University Medical Centre Hamburg-Eppendorf

161  Targeting ADAM17 on human NK cells with a mAb increases their proliferation by IL-15
Bruce Walcheck, University of Minnesota

162  Lysosomal remodeling and granzyme B content define a stable global metric of NK cell function across KIR and HLA genotypes
Camille Philippon, Oslo University Hospital

163  Memory-like NK cells: a promising therapy for Ewing sarcoma
Carla Martín Cortázar, Hospital La Paz Institute for Health Research - IdiPAZ

164  Effect of JAK Inhibition on the Induction of Proinflammatory HLA–DR+CD90+ Rheumatoid Arthritis Synovial Fibroblasts by NK Cell-derived Interferon-?
Carsten Watzl, PhD, Leibniz Research Center Dortmund

165  Transcription factor 19 control of antiviral NK cell immunity
Celeste Dang, Memorial Sloan Kettering

166  Differential cytokine receptor signal regulations by homologous non-receptor protein tyrosine phosphatases in natural killer cells
Chu-Han Feng, Goodman Cancer Research Institute, McGill University

167  Investigation of the expression and function of CD96 (TACTILE) on human uterine NK cells
Corinna Mayer, Karolinska Institutet

168  Assessment of TCR complex expression kinetics in NK cells
Hazel Reilly, Karolinska Institutet

169  Mathematical modeling dissects maturation pathway of natural killer cells in response to mouse cytomegalovirus
Darren Wethington, The Ohio State University

170  Education of uterine natural killer cells by maternal MHC drives fetal growth
Delphine M. Depierreux, University of Cambridge

171  Adaptive NK cells recognize pp65 specific peptides presented by dendritic cells and acquire recall responses
Dhifaf Sarhan, Karolinska Institutet

173  Impact of liver-resident and auto reactive NK cells in the pathogenesis of Primary Biliary Cholangitis
Domenico Mavilio, MD, PhD, Humanitas Clinical and Research Center and University of Milan

174  Polysaccharides from Norwegian Angelica show potent NK cell activation
Emilie S. Ulriksen, University of Oslo

175  Comparing the relative strength of NK receptor-ligand partnerships reveals 2B4 as a dominant signal for NK cell activation
Emily Carter, Dalhousie University

176  Novel two-phase natural killer cell expansion medium preserves NK cell function and activity
Emily Carter, Dalhousie University

177  IRF4 controls NK cell differentiation and clonal expansion during viral infection
Endi K. Santosa, Weill Cornell Graduate School / Memorial Sloan Kettering

178  Additive Effects of Type I Interferons and Galectin-9 on the Suppression of Hepatitis C Virus Infection by Interferon-alpha—activated Natural Killer Cells
Ester Badami, PhD, Fondazione RiMED

179  Characterization of NK cell-mediated anti-viral responses against JC polyomavirus
Esther M. Lee, BA, Duke University

180  NCAM on stromal cells promotes precursor survival and proliferation throughout NK cell development
Everardo Hegewisch-Solloa, Columbia University Irving Medical Center

181  Killer cell immunoglobulin-like receptor-gene content is not associated with COVID-19 severity
Falk Heidenreich, DKMS gGmbH

182  An NKG2A gene polymorphism skews the NK cell repertoire, impacts NK cell function and affects the outcome of immunotherapy in acute myeloid leukemia
Fredrik B. Thoren, PhD, University of Gothenburg

183  Deconvoluting effector states of NK cells in intestinal inflammation and colitis-driven cancer
Gianluca Scarno, Sapienza University of Rome

184  In vivo tumour-induced memory-like Natural killer cells: a phase I trial of INKmune
Helena Arellano-Ballestero, University College London

185  A novel method to produce clinical scale induced pluripotent stem cell-derived natural killer (iPSC-NK) cells with improved anti-tumor activity for next-generation allogenic cell therapies
Huang Zhu, Shoreline Bioscience

186  Marked differences in NK cell phenotype and function between SARS CoV 2-infected individuals with mild and severe disease
Hugh T. Reyburn, PhD, CNB-CSIC

187  Inability to respond to type I interferon signalling has surprisingly little effect on human NK cell development and function
Hugh T. Reyburn, PhD, CNB-CSIC

188  RNA polymerase II pausing in antiviral NK and CD8+ T cells
Hyunu Kim, Gerstner Sloan Kettering Graduate School

189  Hypoxia-Inducible Factor 1 controls Natural Killer cell metabolism
Abigaelle Pelletier, University of Zurich

190  Mechanisms of enhanced antibody dependent cellular cytotoxicity in adaptive natural killer cells
Jenna K. Dick, University of Minnesota

191  Human cytokine-induced memory-like NK cells have a distinct single cell transcriptional and epigenetic profile in vitro and in patients
Jennifer A. Foltz, PhD, Washington University School of Medicine

192  Natural killer cells depend on IRE1’s canonical function for vigorous proliferation during viral infection
Jessica Vetters, VIB-Ugent Center for Inflammation Research

193  Targeting the Spike Protein of SARS-CoV-2 by Natural Killer Cells Engineered with an ACE2-CAR and IL-15 to Treat COVID-19
Jianhua Yu, City of Hope

194  CAR-mediated retargeting of NK cells overcomes tumor immune escape based on ICAM-1 downregulation
Jiri Eitler, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology

195  Fli1 restricts memory precursor NK cell formation during viral infection
Joey Li, UCLA

196  Ly49R activation receptor detection of virus-modified MHC I and antiviral immunity significantly enhanced in self-licensed NK cells
John M. Cronk, University of Virginia

197  Dissecting human uterine immune variation with a focus on natural killer cells
Jonna Bister, PhD student, MD, Karolinska Institutet

198  Partial loss of function mutations in GINS4 lead to natural killer cell deficiency with neutropenia
Jordan S. Orange, MD, PhD, Columbia University

199  Investigating the Role of Natural Killer Cells in the Control of Latent Epstein-Barr Virus Infection
Josselyn K. Pena, Stanford University

200  Antibody ‘Hotspots’ induce antibody-dependent cell-mediated cytotoxicity against SARS-CoV-2 spike-expressing lung fibroblasts
Kayla Holder, Memorial University

201 Hobit confers tissue-dependent programs to type 1 innate lymphoid cells
Kentaro Yomogida, Washington University in St. Louis

202  Natural Killer cell-mediated antibody-dependent cellular cytotoxicity in severe acute respiratory syndrome coronavirus 2-infected individuals and vaccine recipients
Kerri Hagemann, Leibniz Institute for Experimental Virology (HPI)

203  IL-17A producing ILC3 might be involved in duodenal adenoma formation in familial adenomatous polyposis
Kim Kaiser, University Hospital Bonn

204  Immunoglobulin A Fc receptor (CD89)-expressing natural killer cells are enriched in the mucosae and may function as a rheostat for cell signaling and antibody dependent cellular cytotoxicity
Kyle Kroll, Duke University

205  Dynamics of Vg9Vd2 T cell cytotoxic functions at the single cell level
Kyra Kuhnigk, Karolinska Institutet

206  Allele imputation for the Killer cell Immunoglobulin-like Receptor KIR3DL1/S1
Laura Ann Leaton, University of Colorado Anschutz

207  ß-Glucan-Induced IL-10 Secretion by Monocytes Triggers Porcine NK Cell Cytotoxicity
Leen Hermans, Ghent University

208  Dissociation of Human Natural Killer Cell Phenotypic and Transcriptomic Profiles
M. Kazim Panjwani, PhD, Memorial Sloan-Kettering Cancer Center

209  Interrogating the natural killer cell response to COVID-19
Madeline Lee, Stanford University

210  Dissecting the peptide-specificity of inhibitory and activating KIR
Malcolm J. W. Sim

211  UTX is an epigenetic regulator of natural killer cell development and anti-viral effector function.
Mandy Cheng, University of California, Los Angeles

212   Deciphering how natural killer cells kill P. falciparum-infected red blood cells
Maria A. Hernandez Castaneda, University of Minnesota

213  IL-15 priming alters the regulation of IFN-g production in NK cells
Maria Cimpean, Washington University in St Louis

214  Human NK cell function varies across the maternal-fetal interface
Marie Frutoso, Fred Hutchinson Cancer Research Center

215  NK / ILC1 responses to MCMV infection of ovaries and adrenal glands
Marija Mazor, University Of Rijeka

216  The thymus beyond T cell development: Thymic-derived myeloid cells
Mario Ruiz Perez, Sr., PhD, Univesity of Gent

217  Characterization of innate lymphoid cells in the rat and their correlation to gut commensal microbes
Marit Inngjerdingen, University of Oslo

218  Regulation of NK cell development by Fzd5
Mark Owyong, Memorial Sloan Kettering Cancer Center

220  Regulation of Natural Killer Cell Functions by Catecholamines
Martin Obholzer, Leibniz Research Centre for Working Environment & Human Factors

221   Novel NK cell culture medium supports enhanced proliferation and cytotoxic activity of peripheral blood NK cells
Matthew H. Forsberg, PhD, University of Wisconsin-Madison

222  Long-term evolution of the adaptive NKG2C+ NK cell response to cytomegalovirus infection in kidney transplantation: an insight on the diversity of host-pathogen interaction
Michelle Ataya Fernandez, PhD, Fundacio IMIM

223  Insights into NK cell ontogeny in human endometrium from uterus transplant recipients
Paige Porrett, University of Alabama at Birmingham

224  Mature Human NK Cells Require T-bet and Eomes to Maintain Critical Effector Response Mechanisms
Pamela Wong, Washington University in St. Louis School of Medicine

226  SARS-CoV-2 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells
Quirin Hammer, Karolinska Institute

227  The more, the merrier- Subsequent pregnancies are better protected from bacterial infections
Rebecca Kotzur, The Hebrew University Jerusalem

228  NK cells integrate environmental cues to induce DC-mediated cellular immunity to HIV
Renee R. Anderko, PhD, University of Pittsburgh

229  Novel multiplex analyses reveal distinct natural killer cell signaling pathway activation during lentivirus infection
Sho Sugawara, Duke University

230  Fate mapping of single NK cells identifies a type 1 innate lymphoid-like lineage that bridges innate and adaptive recognition of viral infection
Simon Grassmann, Memorial Sloan Kettering Cancer Center

231  RNA sequencing-based comparison of porcine conventional NK cells versus tissue-resident liver NK cells
Sofie Denaeghel, PhD, UGhent University

233  Characterization of Natural Killer Cells in Autoantibody-Mediated Neurological Diseases
Soumya S. Yandamuri, MSE, PhD, Yale School of Medicine

234  Susceptibility of NK cells to hypoxia-adenosinergic immunosuppression
Stephen Hatfield, PhD, Northeastern University

235  Soluble HLA-G activates primary human NK cells through KIR2DL4
Sumi Rajagopalan, PhD, NIAID/NIH

236  Presence of IL-18 secreting Natural Killer B-cells in SIV infected colon which have properties and functions of natural killer cells and B-cells
Sungro Jo, Rush University Medical School

237  TIGIT blockade improves anti-tumor activities of ex vivo expanded NK cells
Faqrul Hasan, University of Central Florida

238  Understanding human NK cell differentiation through investigation of NK cell deficiency
Tessa M. Campbell, Karolinska Institute

239  Impact of genetic polymorphism on NKG2C expression in NK cells, CD8+ T-cells, and Vd1+ T-cells
Theodota Kontopoulos, Memorial Sloan Kettering Cancer Center

241  Fantastic three: the role of CD16, NKG2D and NCR1 in NK cell activation
Vedrana Jelencic, University of Rijeka

242  KIR3DL3 is a polymorphic inhibitory receptor expressed in rare T cell populations.
William H. Palmer, University of Colorado

243  The influence of HLA class I signal peptide polymorphism on HLA-E mediated regulation of NK cells
Zhansong Lin, Ragon Institute of MGH, MIT and Harvard

Last updated: May 12, 2022
NK2022